Compare AbCellera Biologics Inc (ABCL) vs Linde PLC (LIN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Linde PLC — how do they compare? AbCellera Biologics Inc trades at $7.14 (market cap $2.35B), while Linde PLC trades at $530.21 (market cap $248.85B). The key difference: Linde PLC is far larger — about 105.9× AbCellera Biologics Inc's market cap, and Linde PLC pays a 1.19% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | LIN | |
|---|---|---|
Market Cap | $2.35B | $248.85B |
Sector | Health | Basic Materials |
52-Week High | $8.12 | $546.64 |
52-Week Low | $2.78 | $389.38 |
Enterprise Value | $1.99B | $271.21B |
Dividend Yield | — | 1.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Linde (LIN) trades at $540.52, down 1.12% on the day, with a bullish technical outlook supported by moving averages and key resistance at $546. The company reported strong Q1 2026 EPS of $4.33, beating estimates, and maintains robust profitability with a 20.44% net income margin. Recent news highlights sustainability leadership and strategic growth, while cash flow remains positive despite projected 2026 outflows.
Outlook remains positive with 85.7% analyst buy ratings and a $570.80 consensus price target, suggesting 5.6% upside. Risks include rising debt-to-asset ratio (31.63% in 2025) and valuation concerns (P/E 35.84). The stock offers a dividend yield of approximately 0.3% with consistent shareholder returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Linde PLC
Linde is the largest industrial gas supplier in the world, with operations in over 100 countries. The firm's main products are atmospheric gases (including oxygen, nitrogen, and argon) and process gases (including hydrogen, carbon dioxide, and helium), as well as equipment used in industrial gas production. Linde serves a wide variety of end markets, including chemicals, manufacturing, healthcare, and steelmaking. Linde generated approximately $31 billion in revenue and $5 billion in GAAP operating profit in 2021.
Read more on LIN →
